Persistent intestinal abnormalities and symptoms in cystic fibrosis: The underpinning mechanisms impacting gut health and motility. Protocol for a systematic review. by Marsh, Ryan J. et al.
Persistent intestinal abnormalities and symptoms in cystic fibrosis: The 
underpinning mechanisms impacting gut health and motility. Protocol for 
a systematic review. 
 
R.J. Marsh1*, C. Ng2, G. Major2, D.W. Rivett1, A. Smyth2, C.J. van der Gast1 
1Manchester Metropolitan University, Manchester, M1 5GD, UK. 
2University of Nottingham, Nottingham, NG7 2RD, UK. 
 
*Correspondence: RYAN.MARSH@stu.mmu.ac.uk  
Department of Life Sciences, Manchester Metropolitan University, John Dalton 
Building, Chester Street, Manchester, M1 5GD, UK. 
 
  
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 14, 2020. .https://doi.org/10.1101/2020.07.13.20144808doi: medRxiv preprint 
Abstract 
Background  
Patients with cystic fibrosis (CF) are characterised by abnormalities of the 
intestinal tract relating to gut motility and physiological issues, with daily 
symptoms of disease including abdominal pain, flatulence, bloating, and 
constipation. With improvements in respiratory outcomes, a shift in disease 
manifestations has highlighted the prevalence of the gastrointestinal-related 
problems associated with CF, yet most therapies currently in clinical use for the 
gut symptoms of CF have been repurposed from other disease indications and 
have not been developed with a knowledge of the mechanisms underpinning 
gastrointestinal disease in CF. Increased attention towards the role of intestinal 
inflammation and microbial dysbiosis in the CF population warrants a 
comprehensive knowledge of these aspects alongside the increased luminal fat 
content, dysmotility, and small intestinal bacterial overgrowth (SIBO) resultant of 
the primary consequences of CFTR dysfunction (disrupted fluid secretion and 
pancreatic insufficiency), and how they contribute towards the intestinal 
complications of CF disease. 
 
Methods and Study Design 
We will conduct a systematic review to comprehensively address our current 
understanding of the primary consequences of CFTR dysfunction, and their 
subsequent secondary effects that contribute towards the disruption of gut 
motility, health, and associated symptoms in the CF intestine. Databases searched 
will include PubMed, CINAHL, MEDLINE and the Cochrane library from 1939 until 
a specified date of last search, alongside clinical trial databases for ongoing 
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studies. Search strategies will include various terminology that relates to the 
primary mechanistic defects of CF, postulated secondary effects of such defects, 
and symptoms experienced in patients. A full search strategy is outlined in 
appendix B. One reviewer will apply an inclusion criterion to obtained abstracts. 
Following agreement from a second reviewer, full-text articles will be sought, and 
data will be extracted from relevant articles. Disagreements will be resolved with 
a third reviewer. The quality of data will be assessed by the GRADE criteria. Data 
will be used to present a narrative, and where possible, quantitative synthesis.  
 
Discussion  
This systematic review will discuss our current understanding of the underpinning 
mechanisms of the persisting abnormalities in gut health and motility within CF, 
addressing potential intricate relationships that further contribute to disease 
progression within the intestinal tract. Furthermore, we will identify current gaps 
in the literature to propose directions for future research. A comprehensive 
understanding of these aspects in relation to intestinal abnormalities will aid future 
clinical directions. 
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Background 
Description of the condition  
Cystic fibrosis (CF) is the most common life-limiting, autosomal recessive genetic 
disorder, in Europe and North America, with an incidence of about 1 in 2500 births, 
over ten thousand active patients in the UK alone [1], and a significantly higher 
incidence in Caucasians [2]. The underlying cellular mechanisms that are 
disrupted are attributable to mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene, which encodes a cAMP-regulated ATP-
cassette binding protein aptly termed the CFTR protein. CFTR functions to 
transport chloride (Cl-) and bicarbonate (HCO3-) ions at various epithelial sites 
throughout the body, whilst also modulating other ionic movements, such as the 
reabsorption of sodium ions (Na+) via the epithelial sodium channel (ENaC) [3]. 
Such sites of localisation include the respiratory tract, where CFTR mRNA is 
expressed in nasal, tracheal, and bronchial epithelial cells [4], and the 
reproductive tract [5]. As in the airways, the gastrointestinal (GI) tract generally 
expresses higher levels of CFTR mRNA aside from in the stomach. A decreasing 
gradient of expression can be observed from the duodenum to the ileum (proximal 
to distal) inside the small intestine, with expression continuing at a lesser yet 
moderate level within the colon also. Gradients can too be found within the 
subsection of the intestinal region in question. In both small/large intestinal 
environments a crypt-villus gradient is observed in which mRNA expression is 
shown to decrease [6], although this might not be a true representation of protein 
levels given the short life cycle of migrating epithelial cells from crypts that could 
potentially retain and stabilise previously translated protein products. Alongside 
cholangiocytes at the apical surface of the biliary tree [7], both the pancreas and 
gallbladder also express CFTR at high levels with the latter in a more uniform 
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fashion, whereas the pancreas displays more expression within the intercalating 
ducts of the acini [8]. 
Disruption of CFTR production and function in the airway causes dehydration of 
the overlying mucosa, which is also speculated to occur at alternate epithelial 
sites, including the intestines. There is increased viscosity of the mucus layer 
leading to decreased mucociliary clearance in the airway. In the lung, stasis of 
respiratory secretions causes bacterial infections in the airway which are recurrent 
and may become chronic, leading ultimately to bronchiectasis and death from 
respiratory failure. In recent decades, aggressive antibiotic therapy and the use 
of mucolytics and airway clearance has delayed the progress of bronchiectasis. 
This has in turn increased life expectancy for people with CF. A shift in disease 
manifestations has highlighted the prevalence of the gastrointestinal-related 
problems associated with CF. Pancreatic insufficiency has been a recognised 
feature of CF since the first description of the condition [9], arising from the 
disruption of bicarbonate transport and a failure of pancreatic enzyme secretion. 
This is present in 86% of people with CF in the US [10]. Cystic fibrosis liver disease 
(CFLD) has a peak time of onset around puberty and may lead to cirrhosis and 
portal hypertension [11]. A higher prevalence of GI malignancies is seen in older 
individuals with CF, compared to the general population [12]. 
 
Gut health and motility in CF 
Together with the aforementioned manifestations, abnormalities located at the 
site of the intestinal tract itself present problems for CF patients, with quality of 
life affected by daily symptoms which can include abdominal pain, flatulence, 
bloating, and constipation. CF patients may also experience severe 
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gastrointestinal complications that present antenatally or at birth in the form of 
meconium ileus. Highlighted by the accumulation of thick, sticky meconium at the 
terminal ileum and often accompanied by microcolon, it affects around 10-20% of 
newborns with CF [13]. Later in life, a similar phenomenon may occur in the form 
of distal intestinal obstruction syndrome (DIOS). DIOS describes small bowel 
obstruction attributable to the accumulation of partly digested fat at the ileo-
caecal valve. This occurs in around 5% of adults and children with CF annually 
[1]. As both conditions are attributable to mechanical stasis and therefore delayed 
transit of meconium and chyme respectively through the intestinal lumen, this 
could well correlate with the occurrence of small intestinal bacterial overgrowth 
(SIBO), as seen in other GI diseases [14]. CF patients already suffer from 
malabsorption due to failure of pancreatic enzyme and bicarbonate production. 
This may be further worsened by bile salt precipitation and enhanced microbial 
deconjugation of secondary bile acids [15], thereby reducing the effectiveness of 
vitamin absorption in a lipid-dependent manner.  
The CF intestine has received increased attention towards the prevalence of 
chronic inflammation, more recently demonstrated by non-invasive methods of 
quantifying calprotectin and M2-PK levels within stool analysis as used for other 
inflammatory conditions of the intestine [16]. In tandem with the induction of a 
more pro-inflammatory environment in the CF intestines is the presence of a 
general microbial dysbiosis, that is the changes in the structure of the microbial 
community that inhabit this site. There is evidence to suggest a relationship 
between dysbiosis and inflammation, although the levels of bidirectionality within 
this relationship requires further elucidation. In early childhood, a rise in the 
relative abundance of E. coli in CF patients significantly correlates with levels of 
faecal calprotectin [17]. Some species have been assigned as key to optimal gut 
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health, such as prominent members within short-chain fatty acid metabolism and 
resultant butyrate production, which alongside various other beneficiaries to the 
host promotes the suppression of localised inflammatory responses by Treg cell 
expansion [18]. Such species regularly observed in reduced relative abundance in 
CF includes primary degraders such as Ruminococcus bromii and species of 
Bifidobacterium, alongside secondary degraders Faecalibacterium prausnitzii and 
species of Eubacterium and Roseburia [19]. The proposed role of the gut 
microbiome is also extended to include its involvement in the facilitation of 
colorectal cancer development in the CF population [20].  
Many of the previous treatments and lifestyle options implemented to control 
disease-associated complications, such as repeated prophylactic antibiotic 
administration to control respiratory infection and consuming a diet high in fat and 
calorific content to increase low body mass index (BMI), are postulated to 
contribute towards the changes in motility, and health, observed. For example, 
despite the intervention of pancreatic enzyme replacement therapy (PERT), poor 
responses to treatment for a multitude of reasons can still render fat absorption 
incomplete [21]. The administration of antibiotics is often a ‘double-edged sword’, 
which can result in the emergence of opportunistic pathogens and pathobionts 
during the course of microbial resilience. CFTR modulator therapies have emerged 
in recent years with the purpose of correcting the underlying CFTR protein defects 
within processing and gating at the cell surface. Subsequent to the rescue of CFTR 
function, preliminary evidence also suggests shifts in gut microbiome composition 
upon administration alongside other clinical improvements in patients [22].  
This systematic review aims to comprehensively address our current 
understanding of the primary consequences of CFTR dysfunction and their 
subsequent secondary effects in the context of poor intestinal motility, 
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physiological health, and relating symptoms in the CF population. Further, we will 
consider intricate relationships that further aggravate the conditions. We will also 
consider gaps within knowledge and consider the current limitations of study 
within the various animal models and human sampling methods employed. 
 
Description of the interventions 
We will consider any intervention or study that addresses the prevalence and/or 
role of the underpinning mechanisms and their secondary persisting effects that 
lead to negative impacts on gut health and motility in CF. These are outlined in 
the inclusion criteria. 
 
Potential impact of this systematic review 
As the life expectancy of the CF population continues to rise with improvements 
in respiratory outcomes of disease, the incidence of intestinal symptoms and 
manifestations are predicted to increase. Thus, a comprehensive review on the 
underpinning mechanisms contributing towards these recurrent issues in the CF 
population is warranted, allowing for potential targets of therapeutic intervention. 
Most therapies currently in clinical use for the gut symptoms of CF have been 
repurposed from other disease indications and have not been developed with a 
knowledge of the mechanisms underpinning gastrointestinal disease in CF. 
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 Objectives 
To conduct a systematic search of the literature to identify the underpinning 
mechanisms impacting gut health, motility complications, and relating symptoms 
in CF. This includes primary consequences of CFTR dysfunction and their 
subsequent secondary effects contributing towards the development of poor 
intestinal motility, inflammation and other intestinal-based physiological 
complications. 
 
Methods 
Criteria for considering studies for this review 
Types of studies 
The review will include all studies investigating the underpinning mechanisms 
impacting gut health, motility, and relating symptoms in CF. It will include both 
published and ongoing studies. General reviews and expert opinions will be 
omitted from the subsequent narrative or quantitative synthesis of information 
but will be used to attain further primary research data where possible.   
 
Types of participants  
The review will include studies involving participants of any age with a diagnosis 
of cystic fibrosis defined as either having two CF-causing genetic mutations, or 
one or no CF-causing mutations and a sweat chloride test greater than 59mmol/L. 
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CFTR mutant animal models that reflect human intestinal physiology in CF disease 
will be included for selection and discussion.  
 
Types of symptoms and intestinal complications in health and motility 
Symptoms include poor appetite, abdominal pain, flatulence, bloating, and 
constipation. Motility complications will include DIOS and meconium ileus. 
Complications in gut health include malabsorption, intestinal inflammation, 
intestinal lesions and malignancies. 
 
Types of mechanisms and secondary effects considered 
Mechanisms include primary consequences of CFTR dysfunction, such as reduced 
fluid production and the failure of pancreatic enzyme and bicarbonate secretion. 
Subsequent secondary effects considered are increases in luminal fat content, 
microbial dysbiosis, SIBO, and GI dysmotility (increased transit time). A full 
outline of the search strategy is found in appendix A. Any report or article that 
investigates the prevalence or modulation of such mechanisms and/or secondary 
effects in the context of intestinal health and motility will be included.  
 
Types of comparator 
For studies assessing the mechanisms underpinning serious motility complications 
such as DIOS or meconium ileus, this will include both CF and non-CF controls 
who do not present with obstructive DIOS or meconium ileus. For studies 
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investigating mechanisms of malabsorption, intestinal inflammation, intestinal 
lesions and malignancies, this will be healthy controls. 
 
Types of data to be presented 
Primary analysis:  
- Mechanisms and secondary effects underlying DIOS and meconium ileus in CF, 
or their modulation to alleviate such manifestations. 
- Mechanisms and secondary effects underlying malabsorption, intestinal 
inflammation, intestinal lesions, intestinal malignancies, or their modulation to 
alleviate such manifestations. 
 
Secondary analysis:  
- Association of symptoms of GI disorder (poor appetite, abdominal pain, 
flatulence, bloating, and constipation) with motility disorders (DIOS and 
meconium ileus), or other physiological complications of the CF intestine 
(malabsorption, intestinal inflammation, intestinal lesions and intestinal 
malignancies). 
- Investigation of the bidirectional relationships between underpinning 
mechanisms and secondary effects that further accentuates intestinal 
complications. 
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Search methods 
Studies will be identified by searching PubMed, CINAHL, MEDLINE and the 
Cochrane library. The defined search strategies to be used are listed in appendix 
B. This includes variations in search terms used to increase sensitivity. Searches 
will be conducted over the period 1/1/1939 – to present, and only articles 
published in English will be included. In addition, searches will be completed for 
ongoing clinical trials within the EU clinical trials register, Australia and New 
Zealand clinical trials register, ISRCTN and Clinicaltrials.gov. Finally, the reference 
lists of relevant articles and reviews (that may not meet the inclusion criteria) will 
be searched. 
Search results from either databases or clinical trials registers will initially be 
formatted into excel for de-duplication before first selection, and later downloaded 
into Mendeley (v.1.19.4) and checked for duplicates followed by a manual check 
of remaining results.  
 
Data collection and analysis 
Selection of studies 
Titles and abstracts will initially be scanned by one reviewer against the inclusion 
criteria, and those not relevant will be excluded. After co-agreement from a second 
reviewer on primary selection, full text articles will be sought for those articles 
which had met the inclusion criteria based on title or abstract. For articles where 
either the full text article is not available, or is an abstract from a conference, the 
abstracts will be reviewed again. If any meaningful results can be gained from this 
which meet the inclusion criteria these will be included, otherwise they will be 
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excluded. Following second selection, any articles excluded at this stage will have 
the reason for exclusion recorded.  
Where there is disagreement between the two reviewers at any stage of study 
selection, discrepancies will be discussed until an agreement is reached. If an 
agreement cannot be reached, we will ask a third reviewer with no attachment or 
incentives relating to the study. 
 
Data Extraction  
Relevant data from all the included articles after second selection will be placed 
into a data extraction form created on google sheets to facilitate comparisons 
between all studies included. We will analyse the underlying mechanistic themes, 
their secondary effects, and any potential interactions in the context of 
contributing towards the onset of motility disorders, or the disruption of intestinal 
physiology in cystic fibrosis to inform a systematic review.  
 
Quality Assessment  
In order to assess the quality of papers obtained and determine the risk of bias, 
the GRADE criteria will be utilised for each article that passes the second selection 
process. This will allow for us to assess the strengths and limitations of the current 
data from the literature in the context of determining the underpinning CFTR-
related mechanisms and secondary effects attributable to negative impacts of 
motility and health in the intestines of the CF population.  
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Appendix  
A: Criteria for considering studies for this review  
Inclusion  
- Diagnosis of CF: diagnosed on genetic or sweat testing at any age (defined 
as either having two CF-causing genetic mutations, or one or no CF-causing 
mutations and a sweat chloride test greater than 59mmol/L). Animal based studies 
will require the disclosure of the defined genotype eliciting a mutation in the CFTR 
gene. 
- Participants can be of any age therefore the search will include both children 
and adults. Studies which include CF patients where intestinal motility and other 
physiological complications are included as a specific subgroup but analysed 
individually will also be included.  
Type of intervention:  
- Any investigation into the underpinning mechanisms and their secondary 
effects within CF in the context intestinal motility and other intestinal-based 
physiological complications. This could be direct prevalence reporting of 
mechanistic issues and their secondary effects, or further this could be a direct 
study into the modulation of such mechanisms. 
 
- Prevalence: Direct reporting of Pancreatic status, CFTR genotyping to 
describe mutation (fluid secretion) severity, SIBO implied by hydrogen/methane 
breath testing, microbial dysbiosis determined by metagenomic analysis, intestinal 
inflammation by detection of defined markers, dietary fat consumption, capsule 
endoscopy scores, or patient questionnaires/reporting of symptoms. 
 
- Modulation: Any study or intervention utilising probiotics/prebiotics, 
antibiotics, restoration of wild-type CFTR function, modulation of defective CFTR, 
alterations in dietary habits, therapies to increase gut motility, or PERT to increase 
delivery of enzymes to small intestine. 
- Systematic reviews, RCT and observational studies   
- Studies 1/1/1939 – to present  
- Published and currently ongoing trials 
 
Exclusion  
- Any study where mechanism(s) and their postulated secondary effects 
underpinning motility complications (DIOS or meconium ileus), malabsorption, 
intestinal inflammation, intestinal lesions and intestinal malignancies were not the 
focal point of study or analysed individually as part of a larger CF study. 
- Any study looking at the mechanisms underlying inflammation, intestinal 
mucosal damage (lesions), malabsorption, malignancies, or other physiological 
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changes in the intestines not in the context of CF – e.g. Crohn’s disease or 
Ulcerative colitis. 
- Any study looking at the mechanisms underlying dysmotility not in the context 
of CF – e.g. Hirschsprung disease or meconium ileus relating to SGA preterm 
infants. 
- Studies involving non-CF pancreatic insufficiency, such as chronic pancreatitis. 
- Studies investigating alternate pathways or modifier genes in the aetiology of 
cystic fibrosis intestinal complications. 
 
B: Search Criteria 
Date of search: 1-1-1939 to present 
Search terms to be used: 
1. Pancreatic  
2. Enzyme 
3. Pancreas 
4. PERT 
5. Pancreatic insufficiency  
6. Pancreatitis  
7. Bicarbonate 
8. HCO3 
9. Mucus 
10.CFTR dysfunction  
11.CFTR 
12.Restoration  
13.Modulator 
14.Ivacaftor  
15.Lumacaftor  
16.Tezacaftor  
17.Elexacaftor  
18.Orkambi 
19.Symkevi 
20.Trikafta 
21.Kaftrio 
22.Symdeko 
23.Lubiprostone 
24.Dysmotility 
25.Motility 
26.Transit 
27.Small bowel transit 
28.Orocecal transit 
29.Orocaecal transit  
30.Anti-spasmodic 
31.Antispasmodic 
32.Dysbiosis 
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33.Microbiome 
34.Microbiota 
35.Flora 
36.Microflora 
37.Probiotic  
38.Prebiotic  
39.Antibiotic 
40.Fat 
41.Lipid 
42.Diet 
43.SIBO  
44.Small intestinal bacterial overgrowth  
45.Small intestine bacterial overgrowth  
46.Small bowel bacterial overgrowth  
47.Appetite 
48.Abdominal 
49.Abdomen 
50.Flatulence 
51.Bloating 
52.Constipation 
53.Inflammation  
54.Inflammatory  
55.DIOS 
56.Distal intestinal obstruction  
57.Distal intestine obstruction  
58.Ileocecal 
59.Ileocaecal  
60.Ileo-cecal 
61.Ileo-caecal  
62.Meconium ileus 
63.Cystic fibrosis  
64.CF 
65.1 OR 2 OR 3 4 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 
OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 
OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 
OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 
66.47 OR 48 OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 
58 OR 59 OR 60 OR 61 OR 62 
67.63 OR 64 
68.65 AND 66 AND 67 
Databases to be searched: 
PubMed: [Title/Abstract] 
CINAHL: AB 
MEDLINE: .mp. 
Cochrane: ti,ab,kw 
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Clinical trials registers (EU clinical trials register, Australia and New 
Zealand clinical trials register, ISRCTN and Clinicaltrials.gov): 
1. Appetite 
2. Abdominal 
3. Abdomen 
4. Flatulence 
5. Bloating 
6. Constipation 
7. Inflammation  
8. Inflammatory  
9. DIOS 
10.Distal intestinal obstruction  
11.Distal intestine obstruction  
12.Ileocecal 
13.Ileocaecal  
14.Ileo-cecal 
15.Ileo-caecal  
16.Meconium  
17.Cystic fibrosis  
18.1 OR 2 OR 3 4 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 
OR 14 OR 15 OR 16 AND 17 
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